About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

FLX475 in Combination With Ipilimumab in Advanced Melanoma

NCT04894994·4 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

RAPT Therapeutics, Inc., a member of the GSK plc group of companies

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Stage IV or unresectable Stage III advanced melanoma
Prior treatment with at least 2 months of anti-PD-(L)1 agent
Measurable disease at baseline
Tumor available for biopsy

You may not be if

History of allergy or severe hypersensitivity to biologic agents
History of Grade 3-4 immune-related adverse events leading to discontinuation of prior immunotherapy
Prior treatment with ipilimumab or other (cytotoxic T-lymphocyte-associated antigen 4) CTLA-4 antagonists

The record

StatusTerminated

PhasePhase 2

Taking part6

StartedSep 2021

UpdatedDec 5, 2023

Conditions

Advanced Melanoma

Where4

University of California, Los Angeles
Los Angeles, California, United States
Moffitt Cancer Center
Tampa, Florida, United States
Washington University School of Medicine St. Louis
St Louis, Missouri, United States

Clareo Health | FLX475 in Combination With Ipilimumab in Advanced Melanoma